Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02311101 · ClinicalTrials.gov registry record · Phase 1
Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer
A Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT02311101: Completed Phase 1 study, sponsored by The University of Texas Health Science Center at San Antonio.
NCT02311101 is a Phase 1 study that has completed, run by The University of Texas Health Science Center at San Antonio. The registered enrollment target is 18 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02311101, a Phase 1 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The study aims to establish the safety and toxicity of a combined intravesical mitomycin C with BCG for patients with bladder cancer.
Primary Outcome
The primary objective of this study is to determine the MTD for sequential MMC with BCG and thereby establish a recommended phase 2 dose of the combined therapy.
Interventions
- DRUG Mitomycin C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2012-03 |
| Est. Completion | 2015-04 |
| Phase | Phase 1 |
What the finished NCT02311101 record still lists
NCT02311101 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 18 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 1 intervention - of which Mitomycin C is the first listed.
NCT02311101 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02311101 about?
NCT02311101 is a clinical study titled "Phase I Mitomycin Combined With Bacillus Calmette-Guérin (BCG) for Bladder Cancer". The study aims to establish the safety and toxicity of a combined intravesical mitomycin C with BCG for patients with bladder cancer.
What is the current status of trial NCT02311101?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2012-03. Estimated completion is 2015-04.
What interventions are being tested in trial NCT02311101?
The interventions under investigation include: Mitomycin C (DRUG).
Who is sponsoring clinical trial NCT02311101?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02311101's enrollment target sits among peer trials
18 1720th of 2000 higher than 216 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01245179 · 18 participants · Phase 1
Study of Panobinostat (LBH589) in Patients With Sickle Cell Disease
- NCT01999361 · 18 participants · NA
Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss
- NCT02359825 · 18 participants · Phase 1
Nerve Repair Using Hydrophilic Polymers to Promote Immediate Fusion of Severed Axons and Swift Return of Function
- NCT02870244 · 18 participants · Phase 1
Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia